This led to research in the use of liraglutide, semaglutide and tirzepatide for the purpose of chronic weight management
Combining actions that stimulate insulin release and reduce glucagon improves blood sugar stability throughout the day
In Canada, all of these weight loss medications can be used in adult patients with an initial body mass index (BMI) of: 30 Kg/m2 or greater, or 27 Kg/m2 or greater in the presence of at least one weight-related comorbidity (ie, high blood pressure, type 2 diabetes, high cholesterol, fatty liver, sleep apnea, etc) To find out if any of these agents are covered on your benefits plan, use each of the drug identification numbers (DIN) listed below each medication name to check with your benefits plan or pharmacy
When fat cells shrink, they release hormones differently, and this can lead to lighter, heavier, shorter, or longer periods